Clinical Trials Logo

Clinical Trial Summary

This is a Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of NB004 in Subjects with Advanced Solid Tumors


Clinical Trial Description

This study is a Phase 1, open-label, multicenter study of NB004 administered orally in patients with histologically and/or cytologically confirmed diagnosis of advanced solid tumors that are metastatic for which all standard treatment options have been given and are ineffective, or is no longer eligible for additional standard treatment options. The study is comprised of a dose escalation phase to determine the maximum tolerated dose and the RP2D and an expansion phase to further explore the safety and preliminary antitumor activity of NB004. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05036291
Study type Interventional
Source Ningbo Newbay Technology Development Co., Ltd
Contact Yanhua Xu
Phone +8613916714882
Email [email protected]
Status Not yet recruiting
Phase Phase 1
Start date September 3, 2021
Completion date September 26, 2023

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02836600 - A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors Phase 1
Recruiting NCT04890613 - Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation Phase 1
Recruiting NCT04390737 - Evaluate the Safety and Clinical Activity of HH2853 Phase 1
Active, not recruiting NCT04108676 - Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects Phase 1
Recruiting NCT04825392 - A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors Phase 1
Not yet recruiting NCT05001516 - Study of LaNova Medicines(LM)-302 in Patients With Advance Solid Tumors Phase 1/Phase 2
Recruiting NCT04592653 - A Study of ALKS 4230 (Nemvaleukin Alfa) on the Tumor Microenvironment Phase 2
Active, not recruiting NCT03704246 - Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors Phase 2
Recruiting NCT05002270 - JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation Phase 1/Phase 2
Recruiting NCT04478461 - Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Recruiting NCT04135261 - A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors Phase 1
Not yet recruiting NCT05008445 - Study of LM-102 in Patients With Advance Solid Tumors Phase 1/Phase 2
Completed NCT01387321 - A Study of BYL719 in Adult Patients With Advanced Solid Malignancies Phase 1
Recruiting NCT05021367 - A Clinical Study of TQB3823 in Patients With Advanced Malignant Tumor Phase 1
Not yet recruiting NCT05009966 - Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor Phase 1
Not yet recruiting NCT05014828 - To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Patients With Selected Solid Tumors Phase 2
Completed NCT01453387 - MSC2015103B in Solid Tumors Phase 1
Recruiting NCT04805307 - Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 Phase 1
Recruiting NCT04049903 - Study to Investigate the Safety, Blood Levels and Activity of MP0310 (AMG 506) in Patients With Advanced Solid Tumors Phase 1